Compare Adaptive Biotechnologies Corp (ADPT) vs Clorox Co (CLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Clorox Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Clorox Co trades at $94.23 (market cap $11.78B). The key difference: Clorox Co is far larger — about 3.5× Adaptive Biotechnologies Corp's market cap, and Clorox Co pays a 5.09% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CLX | |
|---|---|---|
Market Cap | $3.33B | $11.78B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $131.43 |
52-Week Low | $10.24 | $86.12 |
Enterprise Value | $3.19B | $15.08B |
Dividend Yield | — | 5.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CLX trades at $97.41, up 0.15% on the day, with a neutral technical signal and key support at $96. The company reported Q1 2026 EPS of $1.64, beating expectations, and maintains strong profitability with an 11.18% net margin. Recent news highlights a simplified operating structure and CEO transition, while analyst consensus is a $103.38 price target with a hold-heavy rating distribution.
The outlook is mixed: solid fundamentals and a nearly 5% dividend yield support income investors, but high debt levels and competitive pressures pose risks. Upside depends on execution of new growth initiatives under incoming leadership, with current valuation appearing reasonable relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
